Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer

Tumor Biology

Volumn 31, Issue 4, 2010, Pages 351-357

  Haas, Michael ^a   Laubender, Rüdiger P ^b   Stieber, Petra ^a   Holdenrieder, Stefan ^a   Bruns, Christiane J ^a   Wilkowski, Ralf ^c   Mansmann, Ulrich ^b   Heinemann, Volker ^a   Boeck, Stefan ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c Klinik Bad Trissl   (Germany)

Author keywords

Biomarker; Kinetics; Pancreatic cancer; Second line chemotherapy

Indexed keywords

C REACTIVE PROTEIN; CA 19-9 ANTIGEN; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; CISPLATIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; LACTATE DEHYDROGENASE; OXALIPLATIN; PACLITAXEL; PEMETREXED; RAPAMYCIN; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ACINAR CELL CARCINOMA; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; DISTANT METASTASIS; FEMALE; HUMAN; KINETICS; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SALVAGE THERAPY; SURVIVAL TIME; TREATMENT DURATION; ADENOCARCINOMA; BLOOD; BONE TUMOR; CANCER STAGING; CLINICAL TRIAL; LIVER TUMOR; LUNG TUMOR; METABOLISM; METASTASIS; MIDDLE AGED; PALLIATIVE THERAPY; PANCREAS TUMOR; PATHOLOGY; PERITONEUM TUMOR; SURVIVAL RATE;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; C-REACTIVE PROTEIN; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, ACINAR CELL; FEMALE; HUMANS; KINETICS; L-LACTATE DEHYDROGENASE; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PALLIATIVE CARE; PANCREATIC NEOPLASMS; PERITONEAL NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 77954650702     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-010-0044-6     Document Type: Article

References (30)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-49.
2. Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-13.
3. Heinemann V. Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials. Semin Oncol. 2002;29:9-16.
4. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960-6.
5. Cunningham D, Chau I, Stocken DD, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2009;27:5513-18.
6. Boeck S, Heinemann V. The role of second-line chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer. Future Oncol. 2008;4:41-50.
7. Nakachi K, Furuse J, Ishii H, Suzuki E, Yoshino M. Prognostic factors in patients with gemcitabine-refractory pancreatic cancer. Jpn J Clin Oncol. 2007;37:114-20.
8. Pelzer U, Kubica K, Stieler J, et al. A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results from the CONKO 003 study. J Clin Oncol. 2008;26(Suppl):abstr.4508.
9. Koprowski H, Steplewski Z, Mitchell K, et al. Colorectal carcinoma antigens detected by hybridoma antibodies. Somat Cell Genet. 1979;5:957-71.
10. Lamerz R. Role of tumour markers, cytogenetics. Ann Oncol. 1999;10 suppl 4:145-9.
11. Berger AC, Garcia M, Hoffman JP, et al. Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol. 2008;26:5918-22.
12. Stemmler J, Stieber P, Szymala AM, et al. Are serial CA 19-9 kinetics helpful in predicting survival in patients with advanced or metastatic pancreatic cancer treated with gemcitabine and cisplatin? Onkologie. 2003;26:462-7.
13. Ko AH, Hwang J, Venook AP, et al. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer. 2005;93:195-9.
14. Reni M, Cereda S, Balzano G, et al. Carbohydrate antigen 19-9 change during chemotherapy for advanced pancreatic adenocarcinoma. Cancer. 2009;115:2630-9.
15. Hess V, Glimelius B, Grawe P, et al. CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet Oncol. 2008;9:132-8.
16. Mann DV, Edwards R, Ho S, Lau WY, Glazer G. Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice. Eur J Surg Oncol. 2000;26:474-9.
17. Maréchal R, Demols A, Gay F, et al. Prognostic factors and prognostic index for chemonaíve and gemcitabine-refractory patients with advanced pancreatic cancer. Oncology. 2007; 73:41-51.
18. Sawaki A, Kanemitsu Y, Mizuno N, et al. Practical prognostic index for patients with metastatic pancreatic cancer treated with gemcitabine. J Gastroenterol Hepatol. 2008;23:1292-7.
19. van Cutsem E, Vervenne WL, Bennouna J, et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol. 2009;27:2231-7.
20. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-47.
21. Brambs HJ, Claussen CD. Pancreatic and ampullary carcinoma. Ultrasound, computed tomography, magnetic resonance imaging and angiography. Endoscopy. 1993;25:58-68.
22. Reni M, Berardi R, Mambrini A, et al. A multi-centre retrospective review of second-line therapy in advanced pancreatic adenocarcinoma. Cancer Chemother Pharmacol. 2008;62:673-8.
23. Tanaka T, Ikeda M, Okusaka T, et al. Prognostic factors in Japanese patients with advanced pancreatic cancer treated with single-agent gemcitabine as first-line therapy. Jpn J Clin Oncol. 2008;38:755-61.
24. Tas F, Aykan F, Alici S, et al. Prognostic factors in pancreatic carcinoma: serum LDH levels predict survival in metastatic disease. Am J Clin Oncol. 2001;24:547-50.
25. Kulke MH, Blaszkowsky LS, Ryan DP, et al. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol. 2007;25:4787-92.
26. Boeck S, Wilkowski R, Bruns CJ, et al. Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer. Oncology. 2007;73:221-7.
27. Firpo MA, Gay DZ, Granger SR, et al. Improved diagnosis of pancreatic adenocarcinoma using haptoglobin and serum amyloid A in a panel screen. World J Surg. 2009;33:716-22.
28. Buyse M, Piedbois P. On the relationship between response to treatment and survival time. Stat Med. 1996;15:2797-812.
29. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol. 1983;1:710-19.
30. Nakai Y, Kawabe T, Isayama H, et al. CA 19-9 response as an early indicator of the effectiveness of gemcitabine in patients with advanced pancreatic cancer. Oncology. 2008;75:120-6.